LENSAR placed 15 ALLY Robotic Cataract Laser Systems in Q4 2025, bringing the total ALLY installed base to approximately 200 systems, a 48% increase over December 31, 2024. The company had a backlog of 13 ALLY Systems pending installation as of December 31, 2025. Total laser installed base (LENSAR Laser Systems and ALLY Systems) grew 13% to approximately 435 systems by December 31, 2025. Recurring revenue for the full year 2025 exceeded $46.3 million, an increase of 15% over 2024. Recurring revenue constituted 79% of total revenue for both Q4 2025 and the full year 2025. Worldwide procedure volume increased 22% for the full year 2025 compared to 2024, and approximately 20% in Q4 2025 compared to Q4 2024. Total revenue for Q4 2025 decreased by 4% to $16.025 million compared to $16.731 million in Q4 2024, primarily due to a $2.6 million decrease in system revenue. Total revenue for the full year 2025 increased to $58.435 million from $53.494 million in 2024. Net loss for Q4 2025 significantly decreased to $1.5 million, or ($0.12) per common share, from $18.7 million, or ($1.61) per common share, in Q4 2024. Adjusted EBITDA for Q4 2025 was $0.6 million, up from $0.5 million in Q4 2024. The company retained a $10.0 million merger deposit from the terminated Alcon transaction, which will be recorded as other income in Q1 2026. Cash, cash equivalents, and investments stood at $18.0 million as of December 31, 2025, a decrease from $22.5 million at December 31, 2024.